Partner
Paul Browning, Ph.D., is a first chair litigator focusing on patent litigation and appeals, primarily in the chemical and pharmaceutical areas, including Hatch-Waxman litigation. He has tried cases before judges in various U.S. district courts and has handled arbitrations and mediations. He also advises on patent portfolio strategy with an eye toward success in litigation.
Paul's broad litigation experience includes taking and cross-examining witnesses at trial, briefing and arguing dispositive motions, drafting appellate briefs, and arguing cases on appeal. He has also managed day-to-day litigation activities in actions involving multiple parties. In addition to his litigation practice, Paul advises clients on a variety of patent matters, including strategic development of their patent portfolios and coordination of prosecution and U.S. and foreign litigation strategy and related proceedings before the Patent Trial and Appeal Board (PTAB).
Paul frequently lectures on various topics in chemical patent law and has been recognized as a litigation star by Benchmark Litigation. He designed laser systems and conducted spectroscopy of small molecules while earning master's and Ph.D. degrees at the University of Chicago.
Paul devotes a portion of his practice to pro bono matters and previously led the firm's pro bono committee. He represents military personnel seeking enhanced compensation for injuries received while serving in the military, including injuries received in combat. He also represents veterans in cases before the U.S. Court of Appeals for Veterans Claims and the U.S. Court of Appeals for the Federal Circuit.
Biogen International GmbH v. Teva Pharmaceuticals USA, Inc.
1:17-cv-00829, D. Del., Judge Noreika
1:17-cv-00116, N.D.W. Va., Judge Keeley
Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al.
3:19-cv-13955, 3:19-cv-16305, D.N.J., Judges Wolfson, Arpert
Ferring B.V. v. Allergan, Inc.
Represented Ferring in inventorship litigation, relating to desmopressin pharmaceutical compositions, acting as co-lead counsel at trial.
1:12-cv-02650, S.D.N.Y., Judges Cott, Sweet
Otsuka Pharmaceutical Co., Ltd. v. Apotex Corp.
Represented Otsuka in 24 related Hatch-Waxman litigations concerning Otsuka’s Ability® tablet products and acted as lead counsel on appeal.
1:14-cv-01078, -04671, -02982, -07405, -05878, -06398 -08074 -03306, -06890, -05876, -08077, -03168, -07252, -07105 -05537, -03996, -06158, -04508, -04307, -06397, -07106, -01979, -03445; 1:15-cv-0161, -07584, -01585, -07803, -08830, -05109, -07802, -08955, -01716, -01967, -06353, -08305; 1:16-cv-05288, -05400, -05949, -07705 -02475, -02476, -08284, -05743, -00086, -08085, -00555, -00557, -07346, -06067, -00405, -00424, -05688, -09603; 1:17-cv-02754, -00392, D.N.J., Judges Simandle, Williams
Prosecuting patents for startup Hutchison Medipharma
Finnegan prepared and prosecuted patents for startup Hutchison Medipharma in the United States for the treatment of metastatic colorectal cancer. Those patents cover a small molecule, fruquintinib, which received approval in China.
Finnegan tees up valuable patents for Principia Biopharma, leading to major acquisition deal
Completed successful patent prosecution for Principia. By entrusting Finnegan to obtain strong patents for their Phase 1 candidate, Principia was able to secure an exclusive, worldwide license agreement with Sanofi to develop and commercialize PRN2246, with the potential for $765 million in milestone payments. Finnegan also successfully prosecuted patents directed to compound PRN1008, a BTK inhibitor that Principia is investigating for autoimmune and inflammatory diseases. Principia’s impressive pipeline of drug candidates, covered by a patent portfolio prosecuted by Finnegan, led to an IPO in which Principia raised over $100 million.
Prosecution First Blog
The USPTO’s “Experimental Use Exception Request for Comments” The USPTO’s “Experimental Use Exception Request for Comments”
July 12, 2024
Event
Carolina Patent, Trademark & Copyright Law Association Fall CLE Carolina Patent, Trademark & Copyright Law Association Fall CLE
September 29-30, 2023
Kiawah Island
Event
Proving and Avoiding Inequitable Conduct and Unclean Hands in Patent Prosecution and Litigation Proving and Avoiding Inequitable Conduct and Unclean Hands in Patent Prosecution and Litigation
August 17, 2023
Webinar
Prosecution First Blog
ChromaDex Fails to Milk Its Patent for Subject Matter Eligibility ChromaDex Fails to Milk Its Patent for Subject Matter Eligibility
March 17, 2023
Prosecution First Blog
Inequitable Conduct Claim Can Progress Even After the Case Is Complete Inequitable Conduct Claim Can Progress Even After the Case Is Complete
December 9, 2022
At the PTAB Blog
Inequitable Conduct Claim Can Proceed Even After the Case Is Over Inequitable Conduct Claim Can Proceed Even After the Case Is Over
December 7, 2022
Award/Ranking
Finnegan Ranks at the Top of the Managing Intellectual Property IP Stars Rankings Finnegan Ranks at the Top of the Managing Intellectual Property IP Stars Rankings
June 28, 2024
Managing Intellectual PropertyAward/Ranking
60 Finnegan Attorneys Named to 2023 Capital Pro Bono Honor Roll 60 Finnegan Attorneys Named to 2023 Capital Pro Bono Honor Roll
May 15, 2024
Award/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Benchmark LitigationAward/Ranking
54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll 54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll
July 21, 2023
Press Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyCommentary
Are Winds of Change Finally Blowing on Patent Eligibility? Are Winds of Change Finally Blowing on Patent Eligibility?
December 21, 2022
Law360Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.